COMPOSITE AND INDIVIDUAL MEASURES OF EFFICACY AND SAFETY AFTER 2 YEARS OF UPADACITINIB TREATMENT FOR CROHN'S DISEASE: RESULTS FROM THE ONGOING PHASE 2 CELEST OPEN-LABEL EXTENSION STUDY

Geert R. D'Haens  1     Julian Panés  2     Edouard Louis  3     Qian Zhou  4     John Liu  4     Ana P. Lacerda  4     Edward Loftus  5    
1 AMC Amsterdam Inflammatory Bowel Disease Centre,Amsterdam,Netherlands
2 Hospital Clinic Barcelona,Barcelona,Spain
3 University Hospital of Liège,Liège,Belgium
4 Abbvie,North Chicago,United States
5 Mayo Clinic,Rochester,United States

Citation
United European Gastroenterology Journal 2020; 8 (Supplement 1)


Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Forgot your password?

Reset myUEG password

Social Sharing